Pharmaceutical Manufacturing and Supply of Sumatriptan Succinate Tablets

The contract entails the manufacture and supply of Sumatriptan Succinate Tablets, 100mg, packaged in bottles of nine units, adhering strictly to FDA regulations, current Good Manufacturing Practices, and Department of Defense Logistics Agency technical specifications for packaging, labeling, and storage conditions. The product must remain stable and compliant under controlled room temperature storage of 20–25°C, ensuring pharmacological integrity and regulatory conformity throughout the supply chain. All manufacturing processes, quality controls, and documentation are required to meet the stringent standards mandated by federal and military pharmaceutical guidelines. Performance is to be carried out in support of the Department of Defense, specifically through the Medical Supply Chain Pharm FSA, with the place of performance listed as APO 09094-3219. The contract is structured as a subcontract under NAICS code 325412, indicating its classification within pharmaceutical and medicine manufacturing. The solicitation was posted on July 12, 2026, with a response deadline of July 20, 2026, leaving a limited window for qualified suppliers to submit proposals. The contract is governed by Defense Logistics Agency procurement protocols and is accessible via the DIBBS platform for authorized bidders seeking to fulfill this critical medical supply requirement for U.S. military healthcare operations.